Abstract. Heparin-binding EGF-like growth factor (HB-EGF), but not EGF, binds to cell surface heparan sulfate proteoglycan (HSPG). This was demonstrated in (a) the binding of mI-HB-EGF to mutant CHO cells deficient in HS production was diminished by 70% compared to wild-type CHO cells, (b) the binding of 125I-HB-EGF to CHO cells and bovine aortic smooth muscle cells (BASMC) was diminished 80% by heparitinase or chlorate treatment, and (c) ~zsI-EGF did not bind to CHO cells and its binding to BASMC was not diminished at all by heparitinase and only slightly by chlorate treatment. Accordingly, the role of HB-EGF interactions with HSPG in modulating bioactivity was examined. Heparitinase or chlorate treatment of BASMC diminished the ability of HB-EGF to stimulate BASMC migration by 60-80%. A similar inhibition of migration occurred when BASMC were treated with a synthetic peptide (P21) corresponding to the sequence of the putative heparinbinding domain of HB-EGE As a control for BASMC viability, and for specificity, it was found that heparitinase and P21 did not inhibit at all and chlorate inhibited only slightly the stimulation of BASMC migration by PDGF AB. Since heparitinase, chlorate, and P21 treatment also diminished by 70-80% the crosslinking of mI-HB-EGF to the EGF receptor, it was concluded that the interaction of HB-EGF, via its heparin-binding domain, with cell surface HSPG was essential for its optimal binding to the EGF receptor on BASMC and hence for its optimal ability to stimulate migration.
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H
EPAltlN-binding EGF-like growth factor (HB-EGF)' is a recently described member of the EGF family that was first identified as a secreted product of macrophages and macrophage-like cells (1, 2, 9, 10) . Subsequently, HB-EGF has been found to be expressed by vascular endothelial cells (28) , vascular smooth muscle cells (5, 5a) , and to be a component of wound fluid (17) . HB-EGF, which has been found to contain up to 86 amino acids (10) is significantly longer than EGF and the structurally homologous mitogen, TGF-o~, which have sizes of 53 and 50 amino acids, respectively (4) . The COOH-terminal region of HB-EGF contains six cysteine residues with the spacing characteristic of members of the EGF family (4) and shares ,~40 % sequence identity with EGF and TGF-ot. Comparative structural examination suggests that HB-EGF is analogous to an Please address correspondence to Dr. M. Klagsbrun, Department of Surgery, Children's Hospital, 300 Longwood Avenue, Bostot~, MA 02115. NH2-terminally extended form of EGF and TGF-c~. Since EGF and TGF-a do not bind to heparin (2, 13) while HB-EGF binds tightly to heparin affinity columns and is eluted with 1-1.2 M NaC1 (2, 9, 10), it appeared likely that the heparin-binding domain of I-1B-EGF would be somewhere upstream of the COOH-terminal EGF, TGF-o~-like domain. Site-directed mutagenesis of HB-EGF and studies with peptide fragments have indicated that the heparin-binding sequences of HB-EGF reside primarily in a twenty one-amino acid stretch upstream of and slightly overlapping the EGFlike domain (Thompson, S., S. Rigashiyama, K. Wood, M. Klagsbrun, and J. A6mham, manuscript in preparation).
Abbreviations used in this paper
HB-EGF is as active as PDGF but considerably more potent than EGF or TGF-a in stimulating bovine aortic smooth muscle cells (BASMC) proliferation (9) and migration (as shown in this report). The enhanced potency compared to EGF and TGF-ot occurs despite the fact that all three EGF family members apparently bind to the same high affinity EGF receptor (4, 9) . One possible explanation is differential binding to HSPG. Previous studies have shown that the interaction of two other beparin-binding growth factors, bFGF and vascular endothelial growth factor (VEGF), with cell surface heparan sulfate proteoglycan (HSPG), is an essential requirement for binding to high affinity receptors and for mitogenic activity (7, 15, 24, 27) . These conclusions were based on experiments that used (a) cells mutant in heparan sulfate biosynthesis, (b) cells whose cell surface HSPG was depleted by heparitinase digestion of heparan sulfate, and (c) cells incubated with chlorate to block the sulfation of heparan sulfate. These results suggested that heparin-binding growth factors in general might be dependent on a dual receptor system consisting of HSPG and a high affinity tyrosine kinase receptor that mediates cell signaling. Given that HB-EGF has a strong affinity for immobilized heparin (9), we wanted to determine whether it could bind to cell surface HSPG and whether its bioactivity, in this case the ability to stimulate cell migration, was dependent on interaction with cell surface HSPG. Accordingly, BASMC surface HSPG was altered by heparitinase or chlorate treatment, and a synthetic peptide corresponding to the putative heparin-binding domain of HB-EGF was used to compete for HB-EGF binding to cell surface HSPG. We report here that HB-EGF binds to cell surface HSPG and that the binding of HB-EGF to the EGF receptor on BASMC and its ability to stimulate BASMC migration are considerably diminished when HB-EGF-HSPG interactions are abrogated.
Materials and Methods

Growth Factors
HB-EGF was prepared from U-937 cell conditioned medium as previously described (9, 10) . PDGF AB (23) was obtained from Creative Binmolecules (Hopkinton, MA). EGF (4) was obtained from Collaborative Research (Bedford, MA). HB-EGF (2/tg) was radiolabeled with Na12SI (200 t~Ci/2 /~1; ICN Biomedicals, Costa Mesa, CA) using IODO-BEADS (Pierce, Rockford, IL) as previously reported (10) . The specific activity of 12SI-HB-EGF was 55,500 cpm/ng, as calculated based on the mitogenic activity of radiolabeled HB-EGF for 31"3 cells compared to HB-EGF sta~rds, t2sI-EGF (102,800 cpm/ng) was purchased from Collaborative Research. 1251-bFGF (77,000 cpm/ng) was a kind gif~ of Dr. Brad Olwin (University of Wisconsin).
Cells
BASMC were routinely grown in DMEM supplemented with 10% BCS, 100 U/ml penicillin and 100 t~g/mi streptomycin sulfate (DMEM/10% BCS/PS) as previously described (9, 29) . Wild-type (K1) CHO cells and mutant CHO 803 cells, which synthesize '~,5-10% of the normal amount of HSPG, were routinely grown in Ham's F12 medium supplemented with 10% BCS as previously described (27) .
BASMC Migration
The migration of BASMC was assayed in a Boyden chamber (3, 8) . Subconfluent BASMC were detached from lO-cm culture dishes by incubation with trypsin-EDTA (0.05% trypsin, 0.5 mM EDTA, GIBCO BRL, Gaithersburg, MD) at 370C. To avoid excessive exposure to trypsin, the incubations were carried out for as short a time as possible, usually 1 min or less. The cells were washed first in DMEM, 10% BCS, and then in binding buffer A (DMEM, 20 mM Hepes, pH 7.4, 0.5% BSA) twice, resuspended in the same medium, and the cell number was then adjusted to 105 cells/ml. To set up the migration assay, samples to be tested for stimulation of BASMC migration were first added to the bottom wells of a 48-well Boyden chamber (Neuro Probe Inc., Cabin John, MD) and an 8-/~m pore size polyvinylpyrrolidone-free polycarbonate membrane (Nenro Probe Inc.) precoatad with fibronectin (100 t~g/ml in PBS, Cappel Organou Teknika Corp., West Chester, PA) was placed above these wells. 50 /d of the BASMC suspension were then added to the upper wells of the 48-well chainbar and the chamber was assembled and incubated for 4 h at 37"C in a humidified atmosphere of air/10% CO2. Cells adhering to the upper surface of the filter membrane were renxm~ by scraping with a rubber blade. Cells that had migrated through the filter were fixed with buffered formalin overnight, and then stained with Gill's hematoxylin overnight. The filter was then mounted between two #ass slides with 90% glycerol, and the number of BASMC per well that had migrated across the filter was determined by counting the stained BASMC under a microscope.
Binding Assays
The ability of 125I-HB-EGF to bind to BASMC and CHO cells was measured in binding assays carried out in 6-well plates. Briefly, confluent cells (3 × 105 cells/well) in each well were washed with ice-coid PBS/0.5% BSA, and incubated for 10 min at 4°C with 750-/~1 of ice-cold binding buffer A. 125I-EGF (0.125 ng/750/d/well, 12,800 cpm) or 125I-HB-EGF (0.25 ng/750/~l/well, 13,900 cpm) were added to wells of the plates and the plates were incubated on a shaker at 4°C for 2 h. The wells were then washed three times with ice-cold binding buffer A, and twice with ice-cold PBS/0.5% BSA. Total binding was measured by determining the amount of radioactivity eluted with a wash of 2 M NaCI, 20 mM Na-acetate, pH 4.0 (18, 19, 27) .
Heparitinase and Chlorate Treatment of Cells
BASMC and CHO cells were treated as previously described with heparitinase (24) , in order to digest cell surface heparan sulfate (HS), or with chlorate, an inhibitor of HS sulfation (12, 24) . For heparitinase treatment, BASMC and CHO cells were washed three times with binding buffer A and incubated for 1 h at 37°C with the binding buffer (750 td/6-well plate well, 5 ml/10-cm dish or 10 ml/15-cm dish) containing 0.01 U/ml of heparitinase (Seikagaku America, Inc., Ruekville, MD). A second aliquot of heparitinase was then added to each well or dish to bring the concentration to 0.02 U/ml and the incubation was allowed to proceed for another 2 h. For chlorate treatment, BASMC and CHO cells were incubated with DMEM/10% dialyzed BCS/PS supplememed with 30 mM Na-chlorate for 48 h. Dialyzed BCS was used to diminish the concentration of cysteine (a source of sulfate) tO 50/tM (11, 12) . Heparitinase and chlorate-treated cells were used directly for binding and cross-linking studies, or were trypsinized and analyzed for response to migration factors in a Boyden chamber. It should be noted that chlorate appears to exert a mild toxic effect on cells, possibly due to the long exposure, 48 h, of cells to low cysteine media (12) .
Receptor Cross-linking
Cross-linking of HB-EGF and EGF to the EGF receptor was carried out using methods previously described (26, 27) . Briefly, confluent monolayers of BASMC (107 cells) in 15-cm dishes were washed twice with ice-cold 2 M NaC1, 20 mM Na-acetate, pH 4.0, in order to remove any bound endogenous BASMC-derived I-IB-EGF or EGF. The cells were then washed three times with ice-cold binding buffer B (20 mM Hepes, pH 7.4, 0.5% BSA, 1 mM MgCI2, 1 #M KI in DMEM) and the monolayers were incubated at 4°C for 2 h in binding buffer B containing nSI-HB-EGF (13.3 ng/7.5 ml/15-cm dish, 738000 cpm) or 125I-EGF (9.4 ng/7.5 ml/15-cm dish, 966000 cpm). After the incubation, the cells were washed twice with ice-cold PBS, pH 7.4, containing 0.5% BSA, 1 mM MgCI2, and 1 #M KI, and then twice with ice-cold PBS. Bound t25I-growth factor was crosslinked to cells by the addition of disuc~inimidyl suberate (DSS; Pierce, Rockford, IL) at a final concentration of 30 t~M in PBS for 20 min at room temperature. After free-reactive DSS was quenched with a large excess of 10 mM Tris-HCl, pH 7.5, 150 mM glycine, the cells were washed with icecold PBS, and then scraped and lysed in 400 t~l of lysis buffer (1% Nonidet 
Characterization of a Synthetic Peptide Corresponding to the Heparin-binding Domain of HB-EGF
A synthetic peptide corresponding to the putative 21-amino acid heparinbinding sequence KRKKKGKGLGKKRDPCLRKYK of human HBoEGF (amino acids 93-113 of the 208 residue precursor [9] ) was synthesized using an Applied Biosystems Peptide Synthesizer (courtesy of Margaret Ehrhardt [Brigham and Women's Hospital, Boston, MA]). To determine the effect of P21 on the binding of HB-EGF to heparin-Sepbarose, 40/tl of 50% heparinSepharose (Pharmacia) in 10 mM Tris-HCl, pH 7.4, 0.2 M NaCI, were
Results
HB-EGF
HB-EGF Binds to Cell Surface HSPG
HB-EGF binds to immobilized heparin (2, 9, 10). To demonstrate that HB-EGF can also bind to cell surface HSPG, the ability of ~25I-HB-EGF to bind to CHO cells was measured in several ways (Fig. 1) . CHO cells possess cell surface HSPG but little if any EGF receptor. The binding of '~I-HB-EGF to mutant CHO cells which are deficient in HSPG biosynthesis was diminished by •70% in comparison to the binding of '25I-I-IB-EGF to wild-type CHO cells (Fig. 1 A) . In addition, treatment of CHO cells with heparitinase which degrades cell surface HSPG, or chlorate which inhibits HSPO sulfation, diminished ~I-HB-EGF binding by '~80% (Fig. 1 B) . Taken together, it appears that the binding of HB-EGF to CHO cells is markedly reduced in the absence of HSPG and that therefore I-IB-EGF binds to CHO cell surface HSPG. On the other hand, '25I-EGF did not bind at all to CHO cells consistent with its inability to bind to immobilized heparin (2) (Fig. 1 C) .
Since we were interested in analyzing the role of HSPG in modulating HB-EGF biological activity towards SMC, '25I-HB-EGF binding to BASMC was measured. Unlike CHO cells, SMC mutant in HSPG biosynthesis are not available and these cells possess EGF receptor (9) . Nevertheless, both heparitinase and chlorate diminished total binding of '25I-HB-EGF to BASMC by 80% (Fig. 2) , an amount similar to that produced by these treatments of CHO cells. Thus, it is apparent that HB-EGF binds to BASMC HSPG in addition to the EGF receptor. On the other hand, heparitinase did not diminish at all '2q-EGF binding to BASMC while chlorate reduced 125I-EGF binding by 25%. Taken together, these results suggest that EGF, unlike HB-EGF, binds very poorly, if at all, to BASMC HSPG.
I-HB-EGF ~aSI-HB-EGF [ ~=SI-EGF
EGF mixed with 40 #1 of the same buffer containing increasing amounts of/21 and constant amounts of nsI-I-IB-EGF (0.25 ng, 13,900 cpm), ~25I-EGF (0.125 ng, 12,800 clam ), and 125I-bFGF (0.27 ng, 20,800 cpm). The mixtures were incubated for 5 min at room temperature, after which the heparin
The Ability of HB-EGF to Stimulate BASMC Migration Is Dependent on Interactions with Cell Surface HSPG
It had been previously shown that HB-EGF is a potent mitogenie factor for BASMC, with half-maximal activity at 100 pg/ml (9) . The mitogenic activity of HB-EGF was comparable to PDGF but its specific activity was 30-40 times greater than EGE Using a Boyden chamber migration assay, it is apparent that this is true for migration as well. HB-EGF is a potent stimulator of BASMC migration, with a half-maximal stimulation at 150 pg/mi (Fig. 3) , and 100 pg/mi HB-EGF is as active as 330 pg/mi PDGF AB and 3.3 ng/mi EGE Since I-IB-EGF, but not EGE binds to HSPG, the relationship betw~n growth factor-mediated biological activities and interactions with cell surface HSPG was subsequently analyzed. Migration rather than mitogenic activity was measured in this analysis because the shorter duration of migration assays (4 h) compared to mitogenic assays (72 h) minimized the amount of time needed to measure the effects of growth factors on BASMC treated in various ways. Ac- cordingly, stimulation of migration by HB-EGF was measured on BASMC that had been incubated for either 3 h with heparitinase or for 48 h with chlorate (Fig. 4 A) . Both treatments markedly inhibited the ability of HB-EGF to stimulate migration at all concentrations tested. At the concentration of maximal I-IB-EGF stimulation, 1 ng/rnl, heparitinase or chlorate-treated BASMC migration was diminished by 80%. 1 ng/ml HB-EGF was needed to stimulate the migration of treated BASMC to the same extent as did 150 pg/ml HB-EGF for untreated BASMC. Indeed, the ability of HB-EGF to stimulate BASMC depleted of HSPG was more comparable to that typically seen for EGF on BASMC with a normal complement of cell surface HSPG. Taken together, these results suggested that the ability of HB-EGF to induce migration of BASMC is reduced markedly if the cells are diminished in available or intact cell surface HSPG. For comparison and as a control for SMC viability, the activity of PDGF AB, a potent stimulator of SMC migration (23), was measured on BASMC treated with heparitinase or chlorate (Fig. 4 B) . The ability of PDGF AB to stimulate BASMC migration was not diminished at all by heparitinase suggesting that this treatment was not toxic for SMC nor was the availability of cell surface HSPG an absolute requirement for migration. Chlorate, on the other hand, did diminish PDGF AB-stimulated migration but by only •20%.
Inhibition of HB-EGF-stimulated BASMC Migration by a Heparin-binding Domain Synthetic Peptide Analogue
Another approach to determining the importance of HB-EGF interactions with SMC HSPG would be to interfere with the ability of HB-EGF to bind to cells via its heparinbinding domain. A putative heparin-binding domain in human HB-EGF has been identified by site-directed mutagenesis and peptide fragment studies (Thompson, S., S. . A 21-amino acid synthetic pcptide corresponding to this domain, designated as P21, was prepared and tested for the ability to interfere with the binding of HB-EGF to heparin-Sepharose (Fig.  5 B) . The l~ptide inhibited half-maximally binding of 125I-HB-EGF to heparin-Sepharos¢ at a concentration of ,x,2 mg/ml. On the other hand, I:SI-EGF did not bind to beparin-Sepharose at all consistent with previous observations (13) and therefore was unaffected by P21. Interestingly, the binding of I~I-bFGF, a growth factor with a very strong affinity for heparin and HSPG (13) , to heparin-Sepharose to heparin-Sepharose as described in Materials and Methods. Binding of '251-growth factor in the presence of P21 is plotted relative to control values in the absence of P21 except n5I-EGF which is plotted relative to 125I-HB-EGE Under the conditions of these experiments, the control binding of 125I-bFGF (0.27 ng, 20,800 cpm), 125I-HB-EGF (0.25 ng, 13,900 cpm), t25I-EGF (0.125 ng, 12,800 cpm) to heparin-Sepharose in the absence of P21 was 15,670, 5,600, and 50 cpm, respectively.
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~. was not inhibited by P21 suggesting that bFGF has a different heparin-binding domain than HB-EGE At the concentration of maximal HB-EGF stimulation, 1 ng/ml, the P21 peptide at 25 #g/ml inhibited the ability of HB-EGF to stimulate BASMC migration by •60% (Fig. 6  A) . One ng/ml HB-EGF was needed to stimulate the migration of P21-treated BASMC to the same extent as did 200 pg/ml HB-EGF for untreated BASMC. On the other hand, P21 did not inhibit the ability of PDGF to stimulate BASMC migration demonstrating that the synthetic peptide was not toxic and did not interfere with BASMC migration in a nonspecific manner (Fig. 6 B) . Nor did P21 inhibit any further the relatively poor ability of EGF to stimulate BASMC migration (not shown). Taken together, these results demonstrated further that the ability of HB-EGF to stimulate BASMC migration is modulated by its heparin-binding properties.
Effects of Heparitinase, Chlorate, and 1'21 on Receptor Crass-linking
'25I-EGF and '25I-HB-EGF could both be cross-linked to BASMC to form labeled complexes of '~,170 kD (Fig. 7) . These complexes comigrated with ligand-EGF receptor complex standards prepared by cross-linking 12~I-EGF or '2SI-HB-EGF to A431 cells (not shown), nSI-HB-EGF cross-linking was inhibited by excess cold EGF and 125I-EGF cross-linking was inhibited by excess cold I-IB-EGF supporting the previous conclusion that EGF and I-IB-EGF bind to the same EGF receptor (9) 1-4) 12SI-EGF cross-linking slightly, by ,x,20% (lane 7), consistent with the EGF-BASMC binding studies shown in Fig. 2 .
In conclusion, using several different approaches, it is apparent that the binding of HB-EGF to BASMC surface HSPG is required for its optimal binding to the EGF receptor and that these HB-EGF-HSPG interactions facilitate the ability of I-1B-EGF to stimulate migration of BASMC.
Discussion
HB-EGF, but not the structurally homologous protein EGE is a heparin-binding growth factor (2, 9) . The fact that both HB-EGF and EGF bind to the EGF receptor (9) combined with the possibility that HB-EGF, but not EGE binds to cell surface HSPG, affords an excellent opportunity to ask the question of whether I-IB-EGF binding to HSPG modulates its bioactivity. The ability of HB-EGF to bind to cell surface HSPG can be demonstrated by using mutant CHO cells that synthesize only 5--10% of their normal cell surface HSPG. These HSPG deficient cells bind 125I-HB-EGF only 30% as well as do the wild-type CHO cells. In addition, binding to wild-type CHO cells is diminished by 80% after treatment of cells with heparitinase which destroys cell surface HSPG and with chlorate which blocks sulfation of HSPG. Since we have found that the CHO cells express little if any EGF receptor, these experiments suggest strongly that I-IB-EGF is capable of binding to cell surface HSPG. On the other hand, mz~I-EGF does not bind to CHO cells suggesting a lack of interaction with cell surface HSPG.
To analyze the effects of HSPG on I-IB-EGF bioactivity, we chose to study BASMC because of the previous demonstration that HB-EGF is a far more potent mitogenic factor for these cells than EGF (9) and the subsequent demonstration (Fig. 3 ) that this enhanced potency is true for I-IB-EGF stimulation of BASMC migration as well. It is apparent that HB-EGF binds to BASMC HSPG since treatment of these cells with heparitinase or chlorate diminishes t2~I-HB-EGF binding by "~80%. Using the migration assay, it appears that methods that interfere with HB-EGF-SMC HSPG interactions also inhibit HB-EGF activity. For example, the ability of HB-EGF to stimulate BASMC migration is considerably diminished, by "~70-80%, when these cells are treated with heparitinase or with chlorate. Furthermore, a synthetic peptide, P21, corresponding to the putative heparin-binding domain of HB-EGF (a 21-amino acid stretch just upstream and slightly overlapping the EGF-like domain [Thompson, S., S. Higashiyama, K. Wood, M. Klagsbrun, and J. Abraham, manuscript in preparation] that blocked HB-EGF, but not bFGF, binding to heparin-Sepharose), inhibited HB-EGF stimulation of BASMC migration by ,,060%. As a control for the possibility that heparitinase, chlorate, or P21 treatment might be toxic to BASMC and inhibit migration directly, it was demonstrated that heparitinase and P21 did not diminish at all, while chlorate diminished slightly, the potent ability of PDGF AB to stimulate BASMC migration. It should be pointed out, however, that chlorate treatment resulted consistently in a 20-25 % inhibition of binding and migration, possibly due to cell toxicity caused by the long exposure, 48 h, of BASMC to low cysteine media. The lack of PDGF dependence on HSPG-binding is consistent with the relatively low affinity of PDGF for heparin-Sepharose. PDGF which has a pI of 9.8, is eluted from heparin-Sepharose with 0.5 M NaC1, typical of basic proteins that bind to heparin due to cation-anion charge interactions rather than to any intrinsic heparin affinity (13) . Treatments aimed at abrogating growth factor-HSPG interactions also had no effect on the relatively poor ability of EGF to stimulate BASMC migration consistent with the inability of EGF to bind to immobi-lized heparin or cell surface HSPG. Taken together, it appears that if HB-EGF is prevented access to intact BASMC HSPG by either HSPG degradation, HSPG desulfation, or by a peptide that competes for HB-EGF binding to HSPG, it is no longer optimally bioactive and acts more like EGF, a relatively poor stimulator of BASMC migration.
How do HB-EGF-HSPG interactions modulate bioactivity? In cross-linking experiments in which formation of growth factor-EGF receptor complexes can be visualized and quantitated, it was found that heparitinase-, chlorate-, or P21-treated BASMC display considerably diminished, by ,o70-80%, HB-EGF covalent cross-linking to the tyrosine kinase EGF receptor. On the other hand, heparitinase and P21 had no inhibitory effect and chlorate a slight inhibitory effect on EGF cross-linking to the BASMC EGF receptor consistent with the relative inability of EGF to bind to immobilized heparin or to cell surface HSPG and consistent with the lack in EGF of the heparin-domain present in HB-EGF. These results suggest that the ability of HB-EGF, but not EGF, to bind to the EGF receptor is dependent on its ability to bind to cell surface HSPG. Dependence of HB-EGF binding and bioactivity on a dual receptor system consisting of cell surface HSPG, perhaps acting as low affinity receptors, and the EGF tyrosine kinase receptor, is consistent with results found previously for two other heparinbinding growth factors, bFGF and VEGF (7, 15, 24, 27).
The 
